Xcout Intel
Adocia
Adocia is a clinical-stage biotechnology company that develops innovative formulations of proteins, peptides, and metabolic hormones. The company specializes in creating treatments for diabetes and obesity, as well as immunoprotective scaffolds for cell therapies.
Subscribe to see Adocia’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Adocia at a glance
Adocia is a biotechnology company headquartered in Victor, France. Xcout tracks 16 named people at Adocia, including Kevin Chen (Chairman of the Board & Chief Executive Officer).
Adocia leadership
- Kevin ChenChairman of the Board & Chief Executive Officer
- Bob Yunjun AiChief Financial Officer & Director
- Olivier SoulaChief Executive Officer Co-founder
- Stéphane BoisselChairman of the Board
- Bob Yunjun AiDirector
- Gang LiDirector
10 more named people on record for Adocia, with roles, board committees and tenure — see the full roster →
Adocia competitors
A few of Adocia's closest competitors — see the full list of competitors and alternatives →
AdipoPharma is a French biotech company dedicated to understanding the role of adipocyte cells in diabetes, focusing on lipid biosynthesis and whole-body metabolic health.
DiogenX is a preclinical-stage biotechnology company headquartered in Marseille, France, with research laboratories in Nice, dedicated to developing novel treatments for diabetes.
Atrogi is a clinical-stage biotechnology company headquartered in Stockholm, Sweden, pioneering the development of novel treatments for metabolic disorders.
Biophytis is a clinical-stage biotechnology company that develops transformational therapies to improve longevity and treat age-related diseases. The company utilizes an AI-driven research platform to discover novel drug candidates, with advanced clinical programs focusing on sarcopenia and obesity.
Aspect Biosystems develops bioengineered cellular medicines and implantable tissue therapeutics using a proprietary bioprinting platform that integrates AI, computational design, and advanced biomaterials. The company serves the biotechnology and pharmaceutical industries by creating treatments to replace, repair, or supplement biological functions for metabolic and endocrine diseases.
Parabolica Therapeutics develops proprietary peptide conjugation technologies focused on obesity and other metabolic conditions. The company researches and advances therapeutic programs through its scientific approach.
Get Adocia's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Adocia in Xcout Intel
- 16 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access